From: Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States
cost-effectiveness threshold in GDP per capita/LY (QALY)
Probability of achieving the cost-effectiveness threshold in percent
Germany
United States
LY
QALY
3
0
0.5
0.2
6
87.3
85.6
5.6
4.3
9
100.0
96.4
19.2
11.7